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Stereotactic body radiotherapy (SBRT) is the precise external delivery of very high-dose
radiotherapy to targets in the body, with treatment completed in one to five fractions. SBRT
should be an ideal approach for organ-confined prostate cancer because (I) dose-escalation
should yield improved rates of cancer control; (II) the unique radiobiology of prostate can-
cer favors hypofractionation; and (III) the conformal nature of SBRT minimizes high-dose
radiation delivery to immediately adjacent organs, potentially reducing complications. This
approach is also more convenient for patients, and is cheaper than intensity-modulated
radiotherapy (IMRT). Several external beam platforms are capable of delivering SBRT for
early-stage prostate cancer, although most of the mature reported series have employed
a robotic non-coplanar platform (i.e., CyberKnife). Several large studies report 5-year bio-
chemical relapse rates which compare favorably to IMRT. Rates of late GU toxicity are
similar to those seen with IMRT, and rates of late rectal toxicity may be less than with
IMRT and low-dose rate brachytherapy. Patient-reported quality of life (QOL) outcomes
appear similar to IMRT in the urinary domain. Bowel QOL may be less adversely affected
by SBRT than with other radiation modalities. After 5 years of follow-up, SBRT delivered on a
robotic platform is yielding outcomes at least as favorable as IMRT, and may be considered
appropriate therapy for stage I–II prostate cancer.
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BACKGROUND
Prostate cancer is the most common malignancy in men. An esti-
mated 233,000 cases will be diagnosed in the United States in 2014
(1). PSA screening has led to earlier stage diagnoses; in 1998, 92%
of prostate cancers were diagnosed with clinically organ-confined
disease (2). Based on pre-treatment prognostic parameters, sev-
eral systems have been proposed to stratify prostate cancer into
differing risk groups; these are summarized in Table 1. In 2010,
the seventh edition of the AJCC Staging Manual (3), added Glea-
son score and PSA to the TNM staging system, making these
stage grouping roughly comparable to those of D’Amico and
NCCN, with notable differences in the intermediate- and high-
risk groups. NCCN also adds “very low-risk” and “very high-risk”
categories.
Nearly 50% of patients (4) diagnosed with prostate cancer fall
in prognostic AJCC Stage I, which includes patients with a clini-
cal stage of T1–T2a, PSA< 10, and Gleason 6. Active surveillance
has become a suitable alternative for AJCC stage I, also referred to
as “low-risk,” patients (5). The PIVOT trial randomized PSA-era
diagnosed patients between radical prostatectomy and observa-
tion. The study was not designed to compare outcomes in the
various risk groups, thus firm conclusions about subgroups cannot
be made. Nevertheless, in the PIVOT trial, surgery was associ-
ated with 50 and 60% reductions in prostate cancer deaths for
intermediate- and high-risk groups (D’Amico definition), respec-
tively. This bolsters clinicians’ recommendations that these groups
undergo definitive therapy.
According to the Prostate Cancer Clinical Guideline Panel
of the American Urological Association in 2007 (6), treatment
options that should be discussed include radical prostatectomy,
radiotherapy with or without androgen deprivation, and active
surveillance.
HISTORICAL EVOLUTION OF RADIOTHERAPY FOR PROSTATE
CANCER
Radiotherapy was first used to treat prostate cancer in the first half
of the twentieth century; the application of radium or kilovoltage
therapy yielded disappointing results (7, 8). The development of
megavoltage external beam platforms in the 1950s (9–11) allowed
higher doses to be delivered, with encouraging outcomes. The
next important development was CT imaging and computerized
treatment planning, which facilitated three-dimension confor-
mal external beam planning and intensity-modulated radiother-
apy (IMRT). These more sophisticated treatment plans yielded
better dose conformity to the target, allowing further dose-
escalation. Conformal, dose-escalated techniques have yielded
varying disease-free outcomes, approximately similar to those seen
with radical prostatectomy (see Table 2), although not without
toxicity.
Several randomized trials (22, 27, 28) have confirmed
that dose-escalation yields improved relapse-free survival rates.
Fowler’s dose–response analysis in intermediate-risk patients
(29) (see Figure 1) indicates doses up to around 90 Gy are
necessary to minimize recurrence rates. A meta-analysis of
seven randomized dose-escalation trials yielded the same con-
clusion (30). A variety of strategies have been employed to fur-
ther escalate dose and/or reduce toxicity to surround normal
tissues.
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Table 1 | Risk stratification systems.
Clinical prognostic factors D’Amico NCCN AJCC seventh edition
T1c, PSA<10 ng/ml and PSA density<0.15 ng/ml/g, Gleason ≤6 and
≤3 cores positive, and ≤50% cancer any core
Low-risk Very low-risk Stage I
T1–T2a, PSA<10, Gleason ≤6 Low-risk Low-risk Stage I
T2b or PSA 10–20 or Gleason=7 (single risk factor) Intermediate-risk Intermediate-risk Stage IIa
T2b, PSA 10–20, Gleason=7 (≥2 risk factors) Intermediate-risk Can shift to high-risk Stage IIa
T2c and/or PSA>20 and/or Gleason=8–10 High-risk High-risk Stage IIb
T3b–T4, any PSA, any Gleason Very high-risk Stage III or IV
Table 2 | bDFS outcomes for low-risk prostate cancer.
Rx Institution/author Details Pts Median
F/U years
5-Year bDFS and definition (%)
Nadir+2 ASTRO PSA≥0.2 Averagea
HDR+EBRT Seattle, Kiel, Beaumont (12) 45–50 Gy+2–4 fx boost 46 5 96 92
CA endocurietherapy (13) 36 Gy+5.5–6 Gy×4 boost 70 7.25 93 90
HDR alone CA endocurietherapy (14) 6–7.25 Gy×6 117b 8 96 97
Beaumont (15) 9.5 Gy×4 95c 4.2 98
LDR RTOG 9805 (16) phase II 145 Gy I-125 alone 95 5.3 99 93 88
11 Inst meta-analysis (17) I-125 and Pd-103 alone 1,444 5.25 86 88
External beam Clev Clin (18) hypofract IMRT: 70 Gy, 2.5 Gy/fx 36 5.5 97 97 88
MSKCC (19) IMRT: 81 Gy, 1.8 Gy/fx 203 7 93 85
9 Instit meta-analysis (20) 3-D RT/IMRT: >72 Gy 70 5.7 79
9 Instit meta-analysis (20) 3-D RT/IMRT: 70–76 Gy 231 6.3 95
MDA rand dose-esc (21) 3-D conformal: 78 Gy 32 >5 93 92
MGH, Loma Linda (22) Proton boost to 79.2 Gy 116 5.5 95
Radic prost Baylor: Hull (23) 299 3.9 92.5d 94
Clev Clin, MSK: Kupelian (24) 524 5.5 92
Univ Penn: D’Amico (25) 322 5 88
Johns Hopkins: Han (26) 899 5.9 98
bDFS estimated based on proportions within each risk group.
aWeighted average of ASTRO bDFS or of stated bDFS definition in prostatectomy series.
b75% low-risk, 25% intermediate.
cIncluded T2b in low-risk group.
dPSA≥0.4.
bDFS, biochemical disease-free survival; EBRT, external beam radiotherapy; IMRT, intensity-modulated radiotherapy; LDR, low-dose rate brachytherapy; HDR,
High-dose rate brachytherapy.
Modern radiotherapy plans still had to account for variations
in patient positioning, inaccuracies in treatment delivery, and
internal organ motion. Radiation oncologists account for these
uncertainties by adding a radial margin around the intended tar-
get, creating a “planning target volume (PTV).” This expanded
target extends the high-dose treatment region into the surround-
ing normal structures. A PTV expansion of about 1 cm is required
when skin marks are used for positioning. Set-up uncertainty can
be reduced by placing gold fiducials in the prostate and imaging
prior to treatment delivery. This does not account for movement
within a given treatment session, or “intra-fractional” motion.
Kupelian (31) demonstrated that in 15% of treatment sessions, the
prostate moved more than 5 mm. A study from the Mayo Clinic
(32) recommended a 5-mm margin to account for intra-fractional
motion. The expanded PTV required in IMRT employing pre-
treatment image guidance has limited the maximum safe dose
around 82 Gy, if delivered at 2 Gy per fraction.
Proton therapy offers the prospect of prostate dose-escalation
while limiting exposure to normal tissues. Proton beams deposit
radiation until after passing beyond the target, where the dose
then falls off rapidly. This reduces the radiation dose to normal
tissues, potentially yielding fewer side effects. However, like IMRT,
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FIGURE 1 | Relationship between dose and 5-year freedom from PSA
failure for intermediate-risk patients treated with EBRT [adapted from
Fowler (29)].
proton beam plans must account for prostate motion, thus the
same large PTVs must be targeted. Also, since most proton beam
plans employ only two beams, conformal dose sculpting around
the prostate is not possible. While proton therapy reduces the vol-
ume of normal tissues receiving low dose radiation, large volumes
of the rectum still receive high-dose radiation. In one study (33),
protons yielded a 50% greater incidence of rectal toxicity com-
pared to IMRT. The American College of Radiology Study (03–12)
demonstrated (34) significant (8%) late grade 3+ rectal toxicity
when proton dose was escalated to 82 Gy. Proton dose-escalation
beyond 82 Gy is thus not possible with current technology, and
long-term GI toxicity appears to be no better, and perhaps inferior
to IMRT.
Transperineal ultrasound-guided brachytherapy allows the
delivery of conformal, high-dose radiotherapy to the prostate, with
a rapid dose fall-off outside of the implanted region. In low-dose
rate (LDR) implants, 70–100 iodine-125 (I-125) or palladium-
103 (Pd-103) sources are permanently placed within the prostate;
these“seeds”slowly deliver radiation over the ensuing 2–6 months.
For patients with low-risk prostate cancer, a single LDR implant
(monotherapy) yields favorable long-term outcomes (35–37).
Patients with intermediate- or high-risk disease usually require
a 5-week course of external beam radiotherapy plus the LDR
implant (38, 39). When post-implant dosimetry demonstrates
that the prostate received a biologically equivalent dose (BED)
of around 200 Gy, LDR brachytherapy yields exceptionally high
relapse-free survival rates (40). This is equivalent to about 110 Gy
at 2 Gy/fx, assuming α/β= 1.5. Unfortunately, toxicity following
LDR brachytherapy appears to be greater than IMRT. Fox-Chase
(41) reported 3-year grade 2+ GI and GU toxicities rates were
three and fivefold greater following seed implants. Sanda’s patient-
reported quality of life (QOL) study (42) did not directly compare
treatments, however greater declines in urinary and bowel scores
were observed following brachytherapy than after external beam
radiotherapy.
HYPOFRACTIONATION
High-dose rate (HDR) brachytherapy has been used in the treat-
ment of prostate cancer since the 1980s (43–50). Catheters are
placed temporarily in the prostate, and then loaded with a high-
dose Iridium-192 source, delivering a few fractions of very high-
dose RT. Initial protocols employing HDR combined convention-
ally fractionated external beam RT with an HDR boost. More
recent reports have employed HDR as monotherapy (14, 15,
45, 51–53). Adjusting for pre-treatment risk factors, these stud-
ies yield biochemical disease-free survival (bDFS) outcomes at
least as favorable to those seen with LDR brachytherapy or con-
formal dose-escalated RT or IMRT (see Table 2). A prospective
study from William Beaumont Hospital (15) comparing HDR
monotherapy vs. LDR brachytherapy (Pd-103) showed a supe-
rior 5-year event-free survival (98 vs. 85%, P = 0.01) and a
trend toward improved freedom from cancer failure (98 vs. 92%,
P = 0.1) in the HDR cohort. The same group showed toxicity
and QOL following HDR brachytherapy was more favorable than
either LDR brachytherapy or conformal external beam RT (51,
54). These results suggest prostate cancer favorably responds to
hypofractionated regimens.
Radiation oncologists fractionate RT dose to reduce toxicity
to surrounding normal tissues. For most cancers, by delivering
dose over several weeks, equivalent cancer-killing effect is achieved
with reduced long-term toxicity. The effect of dose fractiona-
tion on both cancer and normal tissues can be estimated using
the “linear-quadratic model.” In this model, the alpha–beta ratio
reflects the response of normal tissues or cancers to changes in
RT dose per fraction. Most cancers respond to RT as do rapidly
dividing normal tissues (e.g., skin or mucous membranes), and
thus have high α/β ratios, in the 8–12 Gy range (55). Tissues with
lower α/β ratios are more sensitive to large dose per fraction (also
known as hypofractionated) RT.
The results of HDR and other hypofractionated regimens led
radiobiologists to reconsider α/β ratio of prostate carcinoma.
Numerous studies have concluded that prostate cancer has an
unusually low/ratio of about 1.5 Gy (29, 56–59). A pooled analysis
(60) of 5,093 patients yielded a α/β ratio of 1.55 Gy. A low α/β
ratio is consistent with other biologic properties of prostate can-
cer: an unusually long tumor doubling times (61), and a very low
proportion of proliferating cells (62). If the α/β ratio for prostate
cancer is smaller than the α/β ratios for late effects in the sur-
rounding normal tissues (3–5 Gy), then a therapeutic gain could
be achieved by hypofractionation. In this setting, larger doses per
fraction should result in equivalent or improved cancer control
with reduced toxicity (63–65).
Several prospective clinical trials have evaluated the efficacy of
hypofractionated radiotherapy in organ-confined prostate cancer.
A large prospective study from the Cleveland Clinic (66) demon-
strated favorable relapse-free survival and low toxicity with 70 Gy
given in 2.5 Gy fractions. A trial from Royal Adelaide Hospital in
Australia (67) randomized 217 patients between 64 Gy in 2 Gy/fx
vs. 55 Gy in 2.75 Gy/fx; these schedules are isoeffective if prostate
α/β= 2.5. The hypofractionated arm showed a significantly bet-
ter bDFS (53 vs. 43%), with equal toxicity in the two arms.
In an Italian trial (68), 168 high-risk patients were randomized
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between 62 Gy in 3.1 Gy/fx vs. 80 Gy in 2 Gy/fx (isoeffective if
prostate α/β= 1.8; both arms received 9 months of androgen abla-
tion). Toxicities were equal. Overall relapse rates were equivalent,
although improved cancer control was suggested if presenting PSA
was 20 or less. Thus, the radiobiologic assertion that the α/β ratio
for prostate cancer is low (1.5–1.8) has been confirmed by class 1
evidence.
Stereotactic body radiotherapy (SBRT) is the precise external
delivery of very high-dose radiotherapy to targets in the body, with
treatment completed in one to five fractions. Dose conformality is
achieved using cross-firing ionizing radiation beams and image-
guidance. By concentrating dose in the targeted cancer, SBRT
maximizes cell-killing. Rapid dose fall-off minimizes radiation-
related injury to adjacent normal tissues. Organ-confined prostate
cancer should be ideally suited for SBRT as (I) dose-escalation
should yield better outcomes; (II) the toxicity from treatment
is due to high-dose radiation exposure to the organs immedi-
ately adjacent to the prostate; and (III) the unique radiobiology of
prostate cancer favors hypofractionation.
SBRT PLATFORMS
Several external beam platforms can theoretically deliver stereo-
tactic radiotherapy for prostate cancer. Table 3 summaries the
capability of these devices. At a minimum, target localization prior
to daily treatments is required. This can be performed using X-ray
imaging of implanted fiducials, or on-board CT imaging. If intra-
fractional image guidance is not employed, then at least 5 mm
PTV expansions are required to account for target motion. If the
target can be localized during treatment, then smaller PTV expan-
sions can be employed, potentially reducing dose to surrounding
organs. The accuracy of different real-time localization systems
can vary considerably. For example, with the Novalis or Varian
TrueBeam systems, typically localization and target positioning
occurs only once prior to each treatment. With the Calypso system,
the operator sets a threshold (typically 3–5 mm) beyond which
treatment is interrupted and the patient positioning corrected.
With the CyberKnife, continuous image acquisition and target
correction occurs routinely; the Stanford group showed that when
intra-fractional correction is done every 40 s, this device achieves
sub-millimeter accuracy (69).
Correction for target motion must account for translational
(i.e., anterior/posterior, right/left, and superior/inferior) motion.
Since rotational motion, particularly pitch, can be substantial, cor-
rection for rotations may be beneficial, although this potential
benefit has not been quantified. The use of multiple non-coplanar
beams should yield better dose conformality than single-plane
treatments. While non-coplanar delivery is possible for any plat-
form, in practice, centers employing gantry-based linacs treat
in a coplanar fashion, as non-coplanar delivery adds complex-
ity and time. The intrinsically non-coplanar CyberKnife platform
is reported (70) to yield more conformal treatment plans than
IMRT.
CLINICAL SBRT OUTCOMES
The first report (71) of hypofractionated stereotactic radiotherapy
treated 40 low-risk patients using a conventional linear acceler-
ator with daily localization of implanted fiducials. 33.5 Gy was
delivered in five fractions to the prostate plus a 4–5-mm margin.
Toxicities were acceptable. Four-year nadir+ 2 bDFS was 90%,
suggesting further dose-escalation would be beneficial.
The feasibility of SBRT employing further dose-escalation
was first reported by King at Stanford University (72) using the
CyberKnife platform. 36.25 Gy in five fractions of 7.25 Gy was
delivered to the prostate plus a 3–5-mm margin. In the most recent
update (73) of long-term outcomes in 67 patients, there were no
grade 4+ toxicities. Two patients had a grade 3 urinary toxic-
ity, and there were no grade 3 GI toxicities. Toxicities compared
favorably to other radiation modalities. Five-year Kaplan–Meier
PSA relapse-free survival was 94%. The majority of subsequent
reports of prostate SBRT have employed the same platform. In a
series of 304 patients treated with CyberKnife at Winthrop hospi-
tal, 5-year bDFS was 97, 90.7, and 74.1% in low-, intermediate-,
and high-risk groups, respectively. Five grade 3 complications
were reported, all GU, for an incidence rate of 2%. In a pooled
analysis of eight institutions (74), 1,100 patients were treated with
CyberKnife SBRT and followed a median of 36 months. Five-year
Table 3 | SBRT platforms.
Platform Description Target localization method Real-time correction Rotational
correction
CyberKnife Linac on robotic arm, non-coplanar
delivery, variable aperture or multileaf
Orthogonal X-rays, image
implanted fiducials
Continuous, automated
sub-millimeter correction
Yes, continuous
automatic
Varian (Trilogy, TrueBeam
etc.), w/Novalis, BrainLab
Linac on gantry. Multileaf collimator.
Volumetric arc therapy available
Cone-beam CT, orthogonal
X-rays, image implanted fiducials
Intermittent; tx interruption
and manual correction
6-D couch
available
Electa (Synergy, VersaHD
etc.)
Linac on gantry. Multileaf collimator.
Volumetric arc therapy available
Cone-beam CT No 6-D couch
available
Calypso Used with gantry-based linacs Implanted beacons provide
real-time localization
Continuous; tx interruption
and manual correction
No
Tomotherapy Linac, helical delivery, multileaf
collimator
Megavoltage CT No No
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Table 4 | Prostate SBRT series with mature follow-up.
Institution Platform Dose
fractionation
Median
F/U years
Risk group Pts 5-Year
bDFSa (%)
Virginia Mason (71) Gantry-based linac 6.7 Gy×5 3.4 Low 40 90b
Stanford (73) CyberKnife 7.25 Gy×5 2.7 Low and low–intermediate 67 94
Stanford, Naples (79) CyberKnife 7–7.25 Gy×5 5 Low and low–intermediate 41 93
Winthrop Hospital (78) CyberKnife 7–7.25 Gy×5 6 Low 324 97
Intermediate 153 91
San Bortolo (80) CyberKnife 7 Gy×5 3 Low, intermediate, and high 100 94
Pooled eight institutions (74) CyberKnife 36–40 Gy in 4–5 fxs 3 Low 641 95
Intermediate 334 84
High 125 81
Katz and Kang (81) CyberKnife 7–7.25 Gy×5 5 High 97 68
Multi-institution (82) CyberKnife 8 Gy×5 3 Intermediate 137 97
Sunnybrook (76) Gantry-based linac 7 Gy×5 4.75 Low 84 97
Twenty-first century (77) Gantry-based linac 8 Gy×5 5 Low 98 99
aNadir+2 definitions.
bFour-year bDFS reported.
bDFS, biochemical disease-free survival; SBRT, stereotactic body radiotherapy.
bDFS rates were 95, 84, and 81% in low-, intermediate-, and high-
risk groups, respectively. In a multi-center study (75), CyberKnife
treated 129 intermediate-risk prostate cancers 40 Gy in five frac-
tions of 8 Gy each, with only one grade 3 toxicity reported (GU:
bladder injury). More recent reports (76, 77) have shown similar
favorable outcomes with gantry-based platforms.
The mature series evaluating dose-escalated SBRT are summa-
rized in Table 4. In low-risk patients treated to 35–36.25 Gy in five
fractions, 5-year bDFS ranges from 94 to 97%. In Katz’s series (78)
of 477 patients with a median follow-up of 6 years, 7-year actuarial
relapse-free survival was 95.6%, confirming durable responses. In
the low-risk patients treated in the eight-institution pooled analy-
sis (74) and in Katz’ series (78), no difference in 5-year bDFS was
seen when dose was escalated from 35 to 40 Gy. Sunnybrook (76)
demonstrated 97% 5-year bDFS in 84 low-risk patients treated
to 35 Gy in five fractions with a gantry-based system. In a series
(77) of 98 low-risk patients treated to 40 Gy in five fractions with
real-time tracking on a gantry-based linac, only one biochemical
failure was reported at 5 years. Current data show no evidence
of a dose–response beyond 7 Gy× 5 in low-risk patients. These
SBRT outcomes compare favorably to the 92–97% 5-year bDFS
typically reported with conventionally fractionated external beam
radiotherapy (see Table 2).
In intermediate-risk patients treated with SBRT, bDFS out-
comes vary. In 153 stage IIa patients from Katz’s series (78), 7-year
bDFS was 90%. In a multi-center study (82) of 137 intermediate-
risk patients given 8 Gy× 5 fractions on the CyberKnife platform,
5-year bDFS was 96%. In a pooled analysis of eight institutions
(74), 5-year bDFS in intermediate-risk patients was only 84%.
However, those patients who received biologically higher doses
(38 Gy in four fractions or 40 Gy in five fractions) had 5-year bDFS
of 96.7%. The apparent improvement in bDFS in the higher-dose
cohort was not statistically significant, and patient populations
were not identical. Katz’s intermediate-risk group had 1/3 Glea-
son 4+ 3 and excluded patients with two high-risk features, while
the multi-institutional study had 20% Gleason 4+ 3 patients,
but included some patients with two high-risk features. Longer
follow-up and comparisons of larger populations will be necessary
to confirm trends suggesting dose-escalation beyond 7.25 Gy× 5
yields better relapse-free survival in intermediate-risk patients.
These SBRT 5-year relapse-free survival rates compare favorably to
fractionated EBRT (22, 83) outcomes, which are typically around
85%. The favorable 5–7-year bDFS rates seen following SBRT may
prove clinically relevant, as IMRT bDFS rates for intermediate-
risk patients steadily drop beyond 5 years. Even at dose levels of
86.4 Gy, 10-year relapse-free survival rate are around 75% (83).
Mature data evaluating SBRT in high-risk prostate cancer are
limited. The largest series is a pooled analysis of eight institutions
(74), in which 125 high-risk patients received CyberKnife with or
without androgen deprivation therapy (ADT). Five-year bDFS was
favorable at 81%. Katz (81) reported on a series of 97 high-risk
patient treated with either five fractions CyberKnife (35–36.25 Gy)
or CyberKnife boost (19–21 Gy in three fractions following 45 Gy
pelvic RT). Forty-six of the 97 patients received ADT. Five-year
bDFS was 68%. The addition of pelvic radiotherapy or ADT had no
impact on relapse-free survival, although pelvic RT was associated
with greater GI toxicity.
ANDROGEN DEPRIVATION THERAPY
Androgen deprivation therapy is routinely added to conventional
RT in unfavorable intermediate-risk and high-risk prostate can-
cer patients (84). In intermediate-risk patients, RTOG 94-08 (85)
demonstrated an overall survival benefit when 4 months of neoad-
juvant hormone therapy (NHT) was added to 66.6 Gy of external
beam RT. We now know higher external beam doses yields bet-
ter outcomes. However, even with modern dose-escalated external
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beam RT, ADT appears to benefit unfavorable intermediate-risk
patients (86). ADT reduces both micrometastatic and local dis-
ease burden; the latter effect may make up for radiotherapy doses
that are inadequate to sterilize the primary disease site. In patients
treated with brachytherapy (which delivers higher biologic doses
to the prostate), a benefit from ADT is unclear, as there are studies
(87, 88) showing conflicting results. The only study evaluating the
impact of ADT on SBRT showed no benefit (81). Even short-term
ADT is associated with hot flashes, erectile dysfunction, muscle
loss, fat accumulation, increased cholesterol, and decreased insulin
sensitivity (89, 90). If dose-escalation obviates the need for ADT
in some subgroups, then SBRT may allow some patients to avoid
the toxicity of ADT. More research is needed in this area.
SBRT TOXICITY
Rates of late physician-reported GI and GU toxicities from mature
SBRT series and from 3-D conformal, IMRT, proton, and LDR
brachytherapy series are summarized in Table 5. Since median
follow-up on the SBRT series is the 3–5-year range, these rates
may underestimate the true rates of toxicities, as more toxici-
ties may develop with longer follow-up. Nevertheless, Figure 2A,
which illustrates the rates of grade 2+ toxicities for various modal-
ities, suggests SBRT late urinary toxicity rates compare favorably
to external beam. Late rectal toxicity rates appear to be consistently
less than those seen with external beam radiotherapy (Figure 2B).
These series employed a robotic non-coplanar delivery platform
which corrected for target motion in real-time (CyberKnife),
although recent reports of SBRT employing conventional gantry-
based platforms (76, 77) also suggest favorable toxicity. A recent
study (91) comparing Medicare claims found SBRT was associated
with 38% more diagnoses of urethritis, incontinence, and obstruc-
tion, compared to IMRT. This study did not evaluate patients
treated with G0339 and G0340 codes (used prior to 2014 with
CyberKnife delivery), so the increased toxicity may be related to
the differences in treatment technique and/or platforms. Finally,
most SBRT series limited PTV doses to 35–40 Gy in five frac-
tions. In a multi-center dose-escalation SBRT study (92), 5 of 91
patients treated to 50 Gy in five fractions required colostomy for
rectal injury. This emphasizes the need to respect dose constraints
for critical structures surrounding the prostate.
PATIENT-REPORTED TOXICITY
Following definitive therapy for prostate cancer, prospective
patient-completed QOL questionnaires more accurately estimate
treatment-related toxicity, compared to physician reports (94, 95).
In Katz’ report of 304 patients treated with CyberKnife SBRT,
urinary and bowel QOL decreased immediately following treat-
ment, and then returned to baseline. Patient-reported QOL out-
comes from a prospective multi-institutional study (82) of 309
patients treated with CyberKnife are illustrated in Figures 3–6
below. QOL outcomes of various organ domains from the val-
idated EPIC instrument are superimposed on the benchmark
external beam and brachytherapy outcomes reported in Sanda’s
(96) study. Long-term changes in urinary incontinence scores fol-
lowing SBRT were similar to those observed in external beam
and in brachytherapy (Figure 3). Urinary irritation/obstruction
scores following SBRT appeared to be less adversely affected than
after brachytherapy (Figure 4). While there were small changes in
bowel QOL following SBRT (Figure 5), these declines appeared
less prominent than following EBRT and brachytherapy. EPIC
sexual score declined progressively during the 4 years after treat-
ment (Figure 6). Because this methodology does not account for
potential differences between SBRT and EBRT/LDR patient pop-
ulations, no firm conclusions can be drawn. Nonetheless, these
patient-reported SBRT QOL outcomes are encouraging.
COST EFFECTIVENESS
Although delivery of SBRT is technically more involved that IMRT,
treatment is completed in only five fractions, rather than the
39–48 fractions required for IMRT. A Markov decision analy-
sis model (97) showed the mean cost of $22,152 for SBRT vs.
$35,431 for IMRT. Another study of Medicare claims (91) reported
mean costs of $13,645 and $21,023 for SBRT and IMRT, respec-
tively. These studies used SBRT billing codes, not the “robotic”
Table 5 |Toxicity rates for SBRT vs. EBRT, protons, brachytherapy.
Technique Institution Details Median F/U years Pts Late GU
toxicity (%)
Late GI
toxicity (%)
Gr2 Gr3 Gr2 Gr3
SBRT (CyberKnife) Stanford (73) 7.25 Gy×5 2.7 67 5.3 3.5 2.0 0
Winthrop Hosp (78) 7–7.25 Gy×5 5.0 304 8.2 1.6 4.6 0
San Bortolo Hosp (80) 7 Gy×5 3.0 100 3.0 1.0 1.0 0
Multi-institutional (75) 8 Gy×5 3.0 137 11.0 0.8 1.0 0
3-D-Conf RT Dutch Random Trial (27) 78.0 Gy 4.2 333 26.0 13.0 27.0 5.0
MDA Random Trial (93) 78.0 Gy 8.7 151 7.3 3.3 19.0 6.6
IMRT Memorial SKCC (83) 86.4 Gy 4.4 478 13.0 2.5 3.3 0.4
Protons MGH PROG (22) 79.2 Gy 8.9 196 21.0 1.5 24.0 1.0
LDR RTOG 9805 (16) 145 Gy 8.1 94 20.0 3.1 5.0 0
SBRT, stereotactic body radiotherapy; IMRT, intensity-modulated radiotherapy; LDR, low-dose rate brachytherapy; RT, radiation therapy.
Frontiers in Oncology | Radiation Oncology April 2015 | Volume 5 | Article 48 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meier Robotic SBRT for stage I–II prostate cancer
FIGURE 2 | Late urinary (A) and GI (B) toxicity rates following SBRT, external beam radiotherapy, and brachytherapy. SBRT, stereotactic body
radiotherapy.
FIGURE 3 | EPIC urinary incontinence scores at baseline and at various intervals following treatment (months) from Sanda (96) (black: left graph is for
external beam RT and right is for brachytherapy) and SBRT (red). SBRT, stereotactic body radiotherapy; RT, radiation therapy.
FIGURE 4 | EPIC urinary irritation/obstruction scores at baseline and at various intervals following treatment (months) from Sanda (96) (black: left
graph is external beam RT and right is brachytherapy) and SBRT (red). SBRT, stereotactic body radiotherapy; RT, radiation therapy.
G-codes used before 2014 for CyberKnife treatment. Since Janu-
ary 1, 2014, CyberKnife treatment also uses the same SBRT codes,
thus these figures are relevant for robotic and non-robotic delivery.
In addition to the cost for treatment, conventionally fractionated
radiotherapy has a substantial time-cost to patients (98), which
is mitigated by the far shorter treatment courses employed with
SBRT.
ONGOING STUDIES
The reported outcomes of SBRT in prostate cancer are derived
from prospective non-randomized studies with the longest median
follow-up extending to approximately 5 years. While these out-
comes appear favorable relative to other radiation modalities,
caution is warranted before concluding SBRT should supplant
conventionally fractionated external beam RT. SBRT target doses,
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FIGURE 5 | EPIC bowel scores at baseline and at various intervals following treatment (months) from Sanda (96) (black: left graph is external beam RT
and right is brachytherapy) and SBRT (red). SBRT, stereotactic body radiotherapy; RT, radiation therapy.
FIGURE 6 | EPIC sexual scores at baseline and at various intervals following treatment (months) from Sanda (96) (black: left graph is external beam
RT and right is brachytherapy) and SBRT (red). SBRT, stereotactic body radiotherapy; RT, radiation therapy.
Table 6 | Randomized SBRT trials registered on clinicaltrials.gov, ISRCTN, and cancerresearchUK.org.
Institution/study Eligibility Arms Primary outcomes
Curie Institute Poland, NCT01839994 T1–T3a N0 M0 76–78 Gy, 2 Gy/fx bDFS, toxicity
50 Gy EBRT+10 Gy×2 SBRT/HDR boost
University of Miami, NCT01794403 T1–T2 N0 M0, low-,
intermediate-risk
70.2 Gy, 2.7 Gy/fx IMRT 2-year bDFS
36.25 Gy, 5 fxs SBRT
University Hosp Geneva, NCT01764646 T1–T3a N0 M0 36.25 Gy SBRT 9 days Acute, late toxicity
36.25 Gy SBRT once/week
Swedish HYPO-RT-PC, ISRCTN45905321 Intermediate-risk 78 Gy, 2 Gy/fx RT bDFS
42.7 Gy, 6.1 Gy/fx
Royal Marsden PACE, CRUKE/12/025 T1–T2 N0 M0 Prostatectomy vs. SBRT (36.25–38 Gy, 4–5 fxs) 5-year bDFS
SBRT vs. conventional RT (78 Gy, 2 Gy/fx)
techniques of RT delivery, image-guidance approaches, and nor-
mal tissue constraints vary considerably between series, making
comparisons difficult. While SBRT toxicities at 3–5 years appear
favorable, higher rates of GU toxicity may be observed with longer
follow-up. Finally, non-randomized comparisons are inherently
uncertain. Firm conclusions about the efficacy and toxicity of
SBRT relative to more conventional approaches await scrutiny by
prospective randomized trials. Randomized trials registered on
clinicaltrials.gov, ISRCTN registry, and cancerresearchUK.org are
summarized in Table 6.
CONCLUSION
Stereotactic body radiotherapy offers a cost-effective alternative
to external beam radiotherapy which is much more convenient
for the patient. The radiobiology of prostate cancer would predict
that this approach should yield superior outcomes compared to
conventional protracted courses. For low-and intermediate-risk
prostate cancer patients treated on a robotic, non-coplanar RT
platform, 5-year relapse-free survival rates are at least equivalent,
or possibly superior to conventionally fractionated RT. Physician-
reported late urinary toxicity appears to be similar to external
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beam RT, and late GI toxicity appears to be less than with external
beam and LDR brachytherapy. Patient-reported QOL outcomes
show urinary and bowel function return to near baseline lev-
els 2 years following robotic SBRT. Long-term changes in rectal
QOL appear to be superior to those reported after IMRT or LDR
brachytherapy. For high-risk prostate cancer, initial CyberKnife
series suggest favorable outcomes. Emerging outcomes in low-risk
patients treated on gantry-based platforms are similarly encourag-
ing. A prospective randomized trial would be required to confirm
these favorable SBRT outcomes relative to other modalities. But
given these excellent cancer control rates and toxicity profiles,
SBRT delivered on platforms which have real-time image guid-
ance appears to be an acceptable approach for stage I–II prostate
cancer. Further studies are also required to determine if similar
favorable outcomes are possible with SBRT delivered on other
platforms, and in patients with high-risk disease.
REFERENCES
1. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin (2014)
64:9–29. doi:10.3322/caac.21208
2. Paquette EL, Sun L, Paquette LR, Connelly R, McLeod DG, Moul JW. Improved
prostate cancer-specific survival and other disease parameters: impact of
prostate specific antigen testing. Urology (2002) 60:756–9. doi:10.1016/S0090-
4295(02)01960-X
3. Edge SB, Byrd DR, Compton CC, et al. editors. AJCC Cancer Staging Manual.
7th ed. New York, NY: Springer (2010).
4. Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, et al. Con-
temporary risk profile of prostate cancer in the United States. J Natl Cancer Inst
(2009) 101:1280–3. doi:10.1093/jnci/djp262
5. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large,
active surveillance cohort with localized prostate cancer. J Clin Oncol (2010)
28:126–31. doi:10.1200/JCO.2009.24.2180
6. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS,
et al. Guideline for the management of clinically localized prostate cancer: 2007
update. J Urol (2007) 177(6):2106–31. doi:10.1016/j.juro.2007.03.003
7. Deming CL. Results in one hundred cases of cancer of prostate and seminal
vesicles, treated with radium. Surg Gynaecol Obstet (1922) 34:99–118.
8. Hultberg S. Results of treatment with radiotherapy in carcinoma of the prostate.
Acta Radiol (1946) 27:339–50. doi:10.3109/00016924609135192
9. Bagshaw MA, Kaplan HS, Sagerman RH. Linear accelerator supervoltage
radiotherapy. VII. Carcinoma of the prostate. Radiology (1965) 95:121–9.
doi:10.1148/85.1.121
10. Budhraja SN, Anderson JC. An assessment of the value of radiotherapy in
the management of carcinoma of the prostate. Br J Urol (1964) 36:535–40.
doi:10.1111/j.1464-410X.1964.tb09544.x
11. George FW, Carlton CE Jr, Dykhuizen RF, Dillon JR. Cobalt-60 telecurietherapy
in the definitive treatment of carcinoma of the prostate: a preliminary report. J
Urol (1965) 93:102–9.
12. Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, et al.
Long-term outcome by risk factors using conformal high-dose-rate brachyther-
apy (HDR-BT) boost with or without neoadjuvant androgen suppression for
localized prostate cancer. Int J Radiat Oncol Biol Phys (2004) 58:1048–55.
doi:10.1016/j.ijrobp.2003.08.003
13. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-
rate intensity-modulated brachytherapy with external beam radiotherapy for
prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol
Biol Phys (2005) 61:1306–16. doi:10.1016/j.ijrobp.2004.08.014
14. Schour L, Demanes DJ, Altieri GA, Brandt D, Barnaba M, Skoolisariyaporn P.
High dose rate monotherapy for prostate cancer. Int J Radiat Oncol Biol Phys
(2005) 63:S315. doi:10.1016/j.ijrobp.2005.07.540
15. Ghilezan M, Vargas C, Gustafson G, Boike T, Chao K, Kestin L, et al. Similar
5-year clinical outcome for high dose rate (HDR) and low dose rate (LDR)
brachytherapy (BT) for early prostate cancer patients. Int J Radiat Oncol Biol
Phys (2005) 63:S37. doi:10.1016/j.ijrobp.2005.07.068
16. Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, et al. Results of
a phase II trial of transrectal ultrasound-guided permanent radioactive implan-
tation of the prostate for definitive management of localized adenocarcinoma
of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys (2007) 67:39–47.
doi:10.1016/j.ijrobp.2010.05.056
17. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, et al. Multi-
institutional analysis of long-term outcome for stages T1-T2 prostate cancer
treated with permanent seed implantation. Int J Radiat Oncol Biol Phys (2007)
67:327–33. doi:10.1016/j.ijrobp.2006.08.056
18. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A.
Hypofractioned intensity-modulated radiotherapy (70Gy at 2.5 Gy per fraction)
for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys
(2005) 63:1463–8. doi:10.1016/j.ijrobp.2005.05.054
19. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term
outcome of high dose intensity modulated radiation therapy for patients with
clinically localized prostate cancer. J Urol (2006) 176:1415–9. doi:10.1016/j.juro.
2006.06.002
20. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, et al. Improved
biochemical relapse-free survival with increased external radiation doses in
patients with localized prostate cancer: the combined experience of nine insti-
tutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys (2005)
61:415–9. doi:10.1016/j.ijrobp.2004.05.018
21. Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, et al.
Dose-response characteristics of low- and intermediate-risk prostate cancer
treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys (2005)
61:993–1002. doi:10.1016/j.ijrobp.2004.04.064
22. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Ran-
domized trial comparing conventional-dose with high-dose conformal radia-
tion therapy in early-stage adenocarcinoma of the prostate: long-term results
from proton radiation oncology group/American college of radiology 95-09. J
Clin Oncol (2010) 28:1106–11. doi:10.1200/JCO.2009.25.8475
23. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW, Scardino PT. Cancer
control with radical prostatectomy alone in 1,000 consecutive patients. J Urol
(2002) 167:528–34. doi:10.1016/S0022-5347(01)69079-7
24. Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, et al. Rad-
ical prostatectomy, external beam radiotherapy <72 Gy, external beam radio-
therapy> or =72 Gy, permanent seed implantation, or combined seeds/external
beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys
(2004) 58:25–33. doi:10.1016/S0360-3016(03)00784-3
25. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA,
et al. Biochemical outcome after radical prostatectomy, external beam radiation
therapy, or interstitial radiation therapy for clinically localized prostate cancer.
JAMA (1998) 280:969–74. doi:10.1001/jama.280.11.969
26. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Bio-
chemical (prostate specific antigen) recurrence probability following radical
prostatectomy for clinically localized prostate cancer. J Urol (2003) 169:517–23.
doi:10.1097/00005392-200302000-00018
27. Peeters ST, Heemsbergen WD, Koper PC, van Putten WL, Slot A, Dielwart
MF, et al. Dose-response in radiotherapy for localized prostate cancer: results
of the Dutch multicenter randomized phase III trial comparing 68 Gy of
radiotherapy with 78 Gy. J Clin Oncol (2006) 24:1990–6. doi:10.1200/JCO.2005.
05.2530
28. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, et al. Prostate
cancer radiation dose response: results of the M. D. Anderson phase III random-
ized trial. Int J Radiat Oncol Biol Phys (2002) 53:1097–105. doi:10.1016/S0360-
3016(02)02829-8
29. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ. What hypofractionated proto-
cols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys (2003)
56:1093–104. doi:10.1016/S0360-3016(03)00132-9
30. Viani GA, Stefano EJ, Afonso SL. Higher-than-conventional radiation doses in
localized prostate cancer treatment: a meta-analysis of randomized, controlled
trials. Int J Radiat Oncol Biol Phys (2009) 74:1405–18. doi:10.1016/j.ijrobp.2008.
10.091
31. Kupelian P, Willoughby T, Mahadevan A, Djemil T, Weinstein G, Jani S, et al.
Multi-institutional clinical experience with the Calypso System in localization
and continuous, real-time monitoring of the prostate gland during external
radiotherapy. Int J Radiat Oncol Biol Phys (2007) 67:1088–98. doi:10.1016/j.
ijrobp.2006.10.026
www.frontiersin.org April 2015 | Volume 5 | Article 48 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meier Robotic SBRT for stage I–II prostate cancer
32. Beltran C, Herman MG, Davis BJ. Planning target margin calculations for
prostate radiotherapy based on intrafraction and interfraction motion using
four localization methods. Int J Radiat Oncol Biol Phys (2008) 70:289–95.
doi:10.1016/j.ijrobp.2007.08.040
33. Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, Stürmer T, et al. Intensity-
modulated radiation therapy, proton therapy, or conformal radiation therapy
and morbidity and disease control in localized prostate cancer. JAMA (2012)
307:1611–20. doi:10.1001/jama.2012.460
34. Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, et al. Acute and
late toxicity after dose escalation to 82 GyE using conformal proton radia-
tion for localized prostate cancer: initial report of American college of radi-
ology Phase II study 03-12. Int J Radiat Oncol Biol Phys (2011) 81:1005–9.
doi:10.1016/j.ijrobp.2010.06.047
35. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Cavanagh W.
Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol
Phys (2000) 46:839–50. doi:10.1016/S0360-3016(99)00499-X
36. Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemi-
cal (prostate-specific antigen) control of prostate cancer with (125)I brachyther-
apy. Int J Radiat Oncol Biol Phys (2001) 51:31–40. doi:10.1016/S0360-3016(01)
01601-7
37. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression
and local control following 125iodine brachytherapy for prostate cancer. J Urol
(2005) 173:803–7. doi:10.1097/01.ju.0000152558.63996.29
38. Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, et al. 12-year
outcomes following permanent prostate brachytherapy in patients with clin-
ically localized prostate cancer. J Urol (2005) 173:1562–6. doi:10.1097/01.ju.
0000154633.73092.8e
39. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen Z, et al.
Impact of supplemental external beam radiotherapy and/or androgen depriva-
tion therapy on biochemical outcome after permanent prostate brachytherapy.
Int J Radiat Oncol Biol Phys (2005) 61:32–43. doi:10.1016/j.ijrobp.2004.05.003
40. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose val-
ues for prostate brachytherapy: effects on PSA failure and posttreatment biopsy
results. Int J Radiat Oncol Biol Phys (2006) 64:527–33. doi:10.1016/j.ijrobp.2005.
07.981
41. Eade TN, Horwitz EM, Ruth K, Buyyounouski MK, D’Ambrosio DJ, Feigen-
berg SJ, et al. A comparison of acute and chronic toxicity for men with low-
risk prostate cancer treated with intensity-modulated radiation therapy or
(125)I permanent implant. Int J Radiat Oncol Biol Phys (2008) 71:338–45.
doi:10.1016/j.ijrobp.2007.10.019
42. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al.
Quality of life and satisfaction with outcome among prostate-cancer survivors.
N Engl J Med (2008) 358:1250–61. doi:10.1056/NEJMoa074311
43. Borghede G, Hedelin H, Holmäng S, Johansson KA, Sernbo G, Mercke C. Irra-
diation of localized prostatic carcinoma with a combination of high dose rate
iridium-192 brachytherapy and external beam radiotherapy with three target
definitions and dose levels inside the prostate gland. Radiother Oncol (1997)
44:245–50. doi:10.1016/S0167-8140(97)00122-9
44. Martinez A, Gonzalez J, Stromberg J, Edmundson G, Plunkett M, Gustafson
G, et al. Conformal prostate brachytherapy: initial experience of a phase
I/II dose-escalating trial. Int J Radiat Oncol Biol Phys (1995) 33:1019–27.
doi:10.1016/0360-3016(95)00254-5
45. Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G.
Phase II prospective study of the use of conformal high-dose-rate brachytherapy
as monotherapy for the treatment of favorable stage prostate cancer: a feasibility
report. Int J RadiatOncol Biol Phys (2001) 49:61–9. doi:10.1016/S0360-3016(00)
01463-2
46. Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L. High dose-rate
after loading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat
Oncol Biol Phys (1998) 41:525–33. doi:10.1016/S0360-3016(98)00097-2
47. Kestin LL, Martinez AA, Stromberg JS, Edmundson GK, Gustafson GS, Brab-
bins DS, et al. Matched-pair analysis of conformal high-dose-rate brachytherapy
boost versus external-beam radiation therapy alone for locally advanced prostate
cancer. J Clin Oncol (2000) 18:2869–80.
48. Kovács G, Galalae R, Loch T, Bertermann H, Kohr P, Schneider R, et al. Prostate
preservation by combined external beam and HDR brachytherapy in nodal
negative prostate cancer. Strahlenther Onkol (1999) 175:87–8. doi:10.1007/
BF03038899
49. Galalae RM, Kovács G, Schultze J, Loch T, Rzehak P, Wilhelm R, et al. Long-term
outcome after elective irradiation of the pelvic lymphatics and local dose esca-
lation using high-dose-rate brachytherapy for locally advanced prostate cancer.
Int J Radiat Oncol Biol Phys (2002) 52:81–90. doi:10.1016/S0360-3016(01)
01758-8
50. Stromberg J, Martinez A, Gonzalez J, Edmundson G, Ohanian N, Vicini F, et al.
Ultrasound-guided high dose rate conformal brachytherapy boost in prostate
cancer: treatment description and preliminary results of a phase I/II clinical
trial. Int J Radiat Oncol Biol Phys (1995) 33:161–71. doi:10.1016/0360-3016(95)
00035-W
51. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, et al.
High dose rate brachytherapy as prostate cancer monotherapy reduces toxic-
ity compared to low dose rate palladium seeds. J Urol (2004) 171:1098–104.
doi:10.1097/01.ju.0000113299.34404.22
52. Martin T, Baltas D, Kurek R, Röddiger S, Kontova M, Anagnostopoulos G, et al.
3-D conformal HDR brachytherapy as monotherapy for localized prostate can-
cer. A pilot study. Strahlenther Onkol (2004) 180:225–32. doi:10.1007/s00066-
004-1215-4
53. Mark R,Vallabhan G, Akins A, Anderson P, Nair M, Neumann T, et al. Interstitial
high dose rate (HDR) brachytherapy for early stage prostate cancer. Int J Radiat
Oncol Biol Phys (2005) 63:S304. doi:10.1016/j.ijrobp.2005.07.521
54. Saputo K, Isler K, Wallace M, Balasubramaniam M, Martinez A. A qual-
ity of life (QOL) assessment of prostate cancer patients undergoing different
radiation treatment modalities. Int J Radiat Oncol Biol Phys (2005) 63:S446.
doi:10.1016/j.ijrobp.2005.07.762
55. Williams MV, Denekamp J, Fowler JF. A review of alpha/beta ratios for exper-
imental tumors: implications for clinical studies of altered fractionation. Int J
Radiat Oncol Biol Phys (1985) 11:87–96. doi:10.1016/0360-3016(85)90366-9
56. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate
carcinoma. Int J RadiatOncol Biol Phys (1999) 43:1095–101. doi:10.1016/S0360-
3016(98)00438-6
57. King CR, Fowler JF. A simple analytic derivation suggests that prostate can-
cer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys (2001) 51:213–4.
doi:10.1016/S0360-3016(01)01651-0
58. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J
RadiatOncol Biol Phys (2001) 50:1021–31. doi:10.1016/S0360-3016(01)01607-8
59. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP.
Direct evidence that prostate tumors show high sensitivity to fractionation (low
alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol
Biol Phys (2002) 52:6–13. doi:10.1016/S0360-3016(01)02664-5
60. Proust-Lima C, Taylor JM, Sécher S, Sandler H, Kestin L, Pickles T, et al. Confir-
mation of a low α/β ratio for prostate cancer treated by external beam radiation
therapy alone using a post-treatment repeated-measures model for PSA dynam-
ics. Int J Radiat Oncol Biol Phys (2011) 79:195–201. doi:10.1016/j.ijrobp.2009.
10.008
61. Lee WR, Hanks GE, Corn BW, Schultheiss TE. Observations of pretreatment
prostate-specific antigen doubling time in 107 patients referred for definitive
radiotherapy. Int J Radiat Oncol Biol Phys (1995) 31:21–4. doi:10.1016/0360-
3016(94)00339-M
62. Haustermans KM, Hofland I, Van Poppel H, Oyen R, Van de Voorde W, Begg
AC, et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol
Phys (1997) 37:1067–70. doi:10.1016/S0360-3016(96)00579-2
63. D’Souza WD, Thames HD. Is the alpha/beta ratio for prostate cancer low? Int J
Radiat Oncol Biol Phys (2001) 51:1–3. doi:10.1016/S0360-3016(01)01650-9
64. Duchesne GM, Peters LJ. What is the alpha/beta ratio for prostate cancer? Ratio-
nale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol
Phys (1999) 44:747–8.
65. Fowler JF, Chappell RJ, Ritter MA. The prospects for new treatments for prostate
cancer. Int J Radiat Oncol Biol Phys (2002) 52:3–5. doi:10.1016/S0360-3016(01)
02665-7
66. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofrac-
tionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for
localized prostate cancer: Cleveland clinic experience. Int J Radiat Oncol Biol
Phys (2007) 68:1424–30. doi:10.1016/j.ijrobp.2007.01.067
67. Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J. Hypofrac-
tionated versus conventionally fractionated radiotherapy for prostate carci-
noma: final results of phase III randomized trial. Int J Radiat Oncol Biol Phys
(2011) 81:1271–8. doi:10.1016/j.ijrobp.2010.07.1984
Frontiers in Oncology | Radiation Oncology April 2015 | Volume 5 | Article 48 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Meier Robotic SBRT for stage I–II prostate cancer
68. Arcangeli S, Strigari L, Gomellini S, Saracino B, Petrongari MG, Pinnarò P, et al.
Updated results and patterns of failure in a randomized hypofractionation trial
for high-risk prostate cancer. Int J Radiat Oncol Biol Phys (2012) 84:1172–8.
doi:10.1016/j.ijrobp.2012.02.049
69. Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of
the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys
(2008) 72:236–46. doi:10.1016/j.ijrobp.2008.04.051
70. Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, et al. Dose
gradient near target-normal structure interface for nonisocentric CyberKnife
and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J
Radiat Oncol Biol Phys (2010) 78:58–63. doi:10.1016/j.ijrobp.2009.07.1752
71. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic
hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in
five fractions for localized disease: first clinical trial results. Int J Radiat Oncol
Biol Phys (2007) 67:1099–105. doi:10.1016/j.ijrobp.2006.10.050
72. King CR, Lehmann J, Adler JR, Hai J. CyberKnife radiotherapy for localized
prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat
(2003) 2:25–30. doi:10.1177/153303460300200104
73. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective
trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat
Oncol Biol Phys (2012) 82:877–82. doi:10.1016/j.ijrobp.2010.11.054
74. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic
body radiotherapy for localized prostate cancer: pooled analysis from a multi-
institutional consortium of prospective phase II trials. Radiother Oncol (2013)
109:217–21. doi:10.1016/j.radonc.2013.08.030
75. Meier R, Cotrutz C, Loiselle C, Sima S, Vermeulen S. Long-term outcomes of
stereotactic body radiation therapy for organ-confined prostate cancer. Int J
Radiat Oncol Biol Phys (2012) 84:S148. doi:10.1016/j.ijrobp.2012.07.1103
76. Loblaw D, Sethukavalan P, Cheung P, Morton G, D’Alimonte L, Deabreu A,
et al. Comparison of biochemical and toxicity outcomes from a contempora-
neous cohort study of low-risk prostate cancer treated with different radiation
techniques. Int J Radiat Oncol Biol Phys (2013) 87:S26. doi:10.1016/j.ijrobp.
2013.06.071
77. Mantz CA, Fernandez E. Real-time target tracking prostate SBRT and the real-
time tracking system 4D localization system: 5-year quality of life and disease
outcomes. Int J Radiat Oncol Biol Phys (2013) 87:S393. doi:10.1016/j.ijrobp.
2013.06.1030
78. Katz A, Kang J. Stereotactic body radiotherapy as treatment for organ con-
fined low-and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol
(2014) 4:240. doi:10.3389/fonc.2014.00240
79. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate can-
cer: five-year outcomes. Radiat Oncol (2011) 6:3. doi:10.1186/1748-717X-6-3
80. Bolzicco G, Favretto MS, Satariano N, Scremin E, Tambone C, Tasca A. A
single-center study of 100 consecutive patients with localized prostate can-
cer treated with stereotactic body radiotherapy. BMC Urol (2013) 13:49.
doi:10.1186/1471-2490-13-49
81. Katz A, Kang J. Stereotactic body radiotherapy with or without external beam
radiation as treatment for organ confined high-risk prostate carcinoma: a six
year study. Radiat Oncol (2014) 9:1. doi:10.1186/1748-717X-9-1
82. Meier R, Kaplan I. Quality of life outcomes from a multicenter study of SBRT for
low- and intermediate-risk prostate cancer. Presented at the 33rd AnnualMeeting
of ESTRO. Vienna: (2014).
83. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelefsky MJ. Long-term sur-
vival and toxicity in patients treated with high-dose intensity modulated radi-
ation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2013)
85:686–92. doi:10.1016/j.ijrobp.2012.05.023
84. Roach M. Current trends for the use of androgen deprivation therapy in
conjunction with radiotherapy for patients with unfavorable intermediate-
risk, high-risk, localized, and locally advanced prostate cancer. Cancer (2014)
120(11):1620–9. doi:10.1002/cncr.28594
85. Jones C. Radiotherapy and short-term androgen deprivation for local-
ized prostate cancer. N Engl J Med (2011) 365(2):107–18. doi:10.1056/
NEJMoa1012348
86. Bian S. Addition of short-term androgen deprivation therapy to dose-
escalated radiation therapy improves failure-free survival for select men with
intermediate-risk prostate cancer. Ann Oncol (2012) 23(9):2346–52. doi:10.
1093/annonc/mds001
87. Stone N. Multicenter analysis of effect of high biologic effective dose on bio-
chemical failure and survival outcomes in patients with Gleason score 7-10
prostate cancer treated with permanent prostate brachytherapy. Int J Radiat
Oncol Biol Phys (2009) 73(2):341–6. doi:10.1016/j.ijrobp.2008.04.038
88. Potters L. 12-year outcomes following permanent prostate brachytherapy in
patients with clinically localized prostate cancer. J Urol (2005) 173(5):1562–6.
doi:10.1097/01.ju.0000154633.73092.8e
89. Watkins Bruner D. Randomized, double-blinded, placebo-controlled crossover
trial of treating erectile dysfunction with sildenafil after radiotherapy and short-
term androgen deprivation therapy: results of RTOG 0215. J Sex Med (2011)
8(4):1228–38. doi:10.1111/j.1743-6109.2010.02164.x
90. Saylor P. Metabolic complications of androgen deprivation therapy for prostate
cancer. J Urol (2009) 181(5):1998–2008. doi:10.1016/j.juro.2009.01.047
91. Yu JB, Cramer LD, Herrin J, Soulos PR, Potosky AL, Gross CP. Stereotac-
tic body radiation therapy versus intensity-modulated radiation therapy for
prostate cancer: comparison of toxicity. J Clin Oncol (2014) 32:1195–201.
doi:10.1200/JCO.2013.53.8652
92. Kim DWN, Cho LC, Straka C, Christie A, Lotan Y, Pistenmaa D, et al. Predictors
of rectal tolerance observed in a dose-escalated phase 1-2 trial of stereotactic
body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys (2014)
89:509–17. doi:10.1016/j.ijrobp.2014.03.012
93. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, et al.
Long-term results of the M.D. Anderson randomized dose-escalation trial for
prostate cancer. Int J Radiat Oncol Biol Phys (2008) 70:67–74. doi:10.1016/j.
ijrobp.2007.06.054
94. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life
outcomes in men treated for localized prostate cancer. JAMA (1995) 273:129–35.
doi:10.1001/jama.1995.03520260051032
95. Talcott JA, Rieker P, Clark JA, Propert KJ, Weeks JC, Beard CJ, et al. Patient-
reported symptoms after primary therapy for early prostate cancer: results of a
prospective cohort study. J Clin Oncol (1998) 16:275–83.
96. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al.
Quality of life and satisfaction with outcome among prostate-cancer survivors.
N Engl J Med (2008) 358:1250–61. doi:10.1056/NEJMoa074311
97. Hodges JC, Lotan Y, Boike TP, Benton R, Barrier A, Timmerman RD. Cost-
effectiveness analysis of stereotactic body radiation therapy versus intensity-
modulated radiation therapy: an emerging initial radiation treatment option
for organ-confined prostate cancer. J Oncol Pract (2012) 8:31s–7s. doi:10.1200/
JOP.2012.000548
98. Yabroff KR, Davis WW, Lamont EB, Fahey A, Topor M, Brown ML, et al. Patient
time costs associated with cancer care. J Natl Cancer Inst (2007) 99:14–23.
doi:10.1093/jnci/djk001
Conflict of Interest Statement: The author declares that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 02 October 2014; paper pending published: 19 October 2014; accepted: 11
February 2015; published online: 07 April 2015.
Citation: Meier R (2015) Dose-escalated robotic SBRT for stage I–II prostate cancer.
Front. Oncol. 5:48. doi: 10.3389/fonc.2015.00048
This article was submitted to Radiation Oncology, a section of the journal Frontiers in
Oncology.
Copyright © 2015 Meier . This is an open-access article distributed under the terms of
the Creative Commons Attribution License (CC BY). The use, distribution or repro-
duction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with
accepted academic practice. No use, distribution or reproduction is permitted which
does not comply with these terms.
www.frontiersin.org April 2015 | Volume 5 | Article 48 | 11
